Drug resistance greatly limits docetaxel efficiency in the treatment of non-small cell lung cancer (NSCLC). Dickkopf 4 (DKK4), a negative regulator of Wnt/β-catenin pathway, is believed to be involved in various human cancers; whereas the association of DKK4 with acquired docetaxel resistance in NSCLC remains unclear. In the present study, we investigated the involvement of DKK4 in the docetaxel-resistant human lung adenocarcinoma A549 (A549/DTX) cells. Our results showed that DKK4 expression was significantly increased in the A549/DTX cells compared with in the A549 cells, as well as in the culture supernatant of A549/DTX cells. DKK4 overexpression increased the resistance of A549 cells to docetaxel. DKK4-knockdown promoted inhibition of A549/DTX cell growth, and reduced the colony formation and invasion capacity of A549/DTX cells. Moreover, DKK4-knockdown promoted the pro-apoptotic effect of docetaxel characterized with caspase 3 activation and inhibition of BCL-2 expression in A549/DTX cells, which was possibly mediated by inducing the activation of c-Jun N-terminal kinase (JNK)-related signaling pathway. Thus, our results indicated that DKK4-knockdown promoted the cytotoxic and pro-apoptotic activity of A549/DTX cells, which suggests a critical role of DKK4 in docetaxel resistance of the A549 cells and provides the potential to combine docetaxel therapy with DKK4 depletion in treating NSCLC.
Introduction
Lung cancer is becoming one of the leading causes of cancer death worldwide [1] . The majority of lung cancers are non-small cell lung cancer (NSCLC) which accounts for~85% of lung cancers [2, 3] . Due to tumor recurrence and metastasis, lung cancer is known to be a highly treatment-refractory cancer. For advanced-stage of lung cancer, chemotherapy has been the ideal treatment option [4, 5] . However, a large number of advanced NSCLC patients are not sensitive to chemotherapy for the reason of drug resistance. Thus, it makes NSCLC treatment a great challenge for clinical therapy. As a chemotherapeutic agent for NSCLC treatment, docetaxel administration shows great efficacy, and now it is widely used in the second line treatment of NSCLC [6] . However, the problem is that docetaxel resistance has greatly limited the life-expanding effect of this chemotherapeutic agent [7] . Understanding the molecular mechanism underlying such chemoresistance phenomena is fundamental to the development of therapeutic strategies to overcome this adverse effect.
The DKK family, known to antagonize Wnt/β-catenin signaling, is important for vertebrate development by inhibiting Wnt-regulated processes such as antero-posterior axial patterning, limb development, somitogenesis, and eye formation [8] . DKKs comprise four secreted glycoproteins including DKK1, DKK2, DKK3, and DKK4 [8] .
The four members exert different effects on Wnt/β-catenin signaling, and their mechanism of action has not been fully delineated [9] . Due to the fact that Wnt proteins participate in various types of cancer development and progression, the associations of DKKs with cancer are also widely concerned. Of the four members, DKK4 was implicated in vertebrate development, such as bone formation and meibomian gland development [10, 11] . In addition, recent studies have also revealed the abnormal expression of DKK4 in a broad range of solid tumors including colorectal, renal, liver, and pancreatic carcinomas, which indicates the significant association of DKK4 with cancer [12] [13] [14] [15] . However, the role of DKK4 has not been widely investigated in lung cancer, and the association of DKK4 with acquired docetaxel resistance in NSCLC has not been elucidated.
In the present study, the involvement of DKK4 in the docetaxelresistant human lung adenocarcinoma A549 (A549/DTX) cells was investigated for the first time. In addition, the underlying molecular mechanisms of such effect were also explored.
Material and Methods

Cell lines and culture
The human lung adenocarcinoma A549 cells were purchased from ATCC (Manassas, USA). A549/DTX cells were selected by continuous exposure to increasing concentration of docetaxel (Sigma Aldrich, St Louis, USA). A549 cells were treated with docetaxel at 2.5 and 5 μg/l for 48 h. After treatment, the surviving cells were re-seeded into new flasks and allowed recover for 2 weeks. The above procedure was repeated for~6 times. The doses of docetaxel were increased to 10 and 15 μg/l, respectively, for~6 cycles again. After each treatment, the A549 cells were allowed to adequately recover before evaluating the resistance to docetaxel. Finally, the acquired A549/DTX cells were cultured in Dulbecco's modified Eagle's medium (DMEM; GibcoBRL Life Technologies, Grand Island, USA) containing 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamine. Cell cultures were maintained in a humidified atmosphere with 5% CO 2 at 37°C.
DKK4 assay by ELISA
The concentration of DKK4 was detected using ELISA kit (R&D System, Minneapolis, USA). Briefly, 100 μl sample or standard was added into each well of the 96-well plate. The wells were covered with adhesive strips and incubated for 2 h at room temperature. Wells were washed three times with washing buffer followed by incubation with 100 μl detection antibody for 2 h at room temperature. After three times wash with washing buffer, wells were incubated with 100 μl working dilution of Streptavidin-HRP for 30 min at room temperature. Then, wells were washed for another three times with washing buffer followed by incubation with 100 μl of substrate solution at room temperature for 20 min. Finally, 50 μl of stop solution was added into each well. The optical density of each well was determined using an ELISA Multiskan MK3 reader (Thermo Scientific, Hudson, USA) at 450 nm.
DKk4 overexpression by transfection
Plasmid that contained the human full-length combinational DNA fragment of DKK4 was purchased from Origene (Rockville, USA). This plasmid (pCMV6-DKK4) expresses the complete DKK4 open reading frame. A549 cells were transfected with pCMV6 control vector or pCMV6-DKK4 plasmid using Lipofectmine 2000 (Invitrogen, Grand Island, USA). Transfected cells were grown in DMEM with 10% FBS for the subsequent experiments.
DKK4-knockdown by siRNA A549/DTX cells were cultured overnight and then transfected with siRNA (sense 5′-AGGAAGCAGAGAAACCCGGC-3′) targeting DKK4 (Santa Cruz Biotechnology, Santa Cruz, USA) or with scrambled siRNA (sense 5′-GAACCGAGCGAAGCAGGAAC-3′) as a negative control (Santa Cruz Biotechnology) by using siRNA Transfection Reagent (Santa Cruz Biotechnology). Cells were incubated in DMEM for another 48 h after transfection.
Real time-PCR analysis
Total RNA was isolated from cultured cells using Trizol reagent (Invitrogen Life Technologies, Carlsbad, USA). Quantitative analysis of mRNA was performed with the ABI7500 sequence detection system (Life Technologies, Grand Island, USA) using SYBR green PCR Master Mix (TaKaRa, Dalian, China). The primers for DKK4 and β-actin were as follows: DKK4, sense primer 5′-CTGACACGGACT GCAATACC-3′ and anti-sense primer 5′-CTCATCAAGCTGCCTTT CTAAT-3′; β-actin, sense primer 5′-TGACGTGGACATCCGCAAA G-3′, and anti-sense primer 5′-CTGGAAGGTGGACAGCGAGG-3′. Each sample was run in three duplicates. β-Actin was used as an endogenous control.
Western blot analysis
A549/DTX cells were harvested, washed with cold PBS, and lysed with ice-cold lysis buffer supplemented with protease inhibitors. Cell lysate was run on 10% sodium dodecylsulphate polyacrylamide gel electrophoresis and then transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, USA). The membrane was then blocked with 5% bovine serum albumin (BSA) in Tris-buffer saline with 0.1% Tween 20 for 1 h, followed by incubation with primary antibody at 4°C overnight. The primary antibodies included antibodies against p-JNK (9251 s), JNK (9252 s), caspase 3 (9662 s), BCL-2 (4223 s), and β-actin (4967 s), which were all from Cell Signaling Technology (Danvers, USA). After extensive wash, the membrane was incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies (Dingguo Changsheng, Beijing, China) for 1 h at room temperature. After extensive wash, membrane was detected using an ECL detection kit (Millipore).
Cell viability assay
Cell viability was analyzed as previously described [16] . Cells were seeded in 96-well plates at a density of 1 × 10 4 cells/well and incubated with docetaxel (Sigma-Aldrich) for 48 h. The final concentrations of docetaxel were applied with double dilution from 1920 to 15 μg/l. Then, 20 μl of MTT (Sigma-Aldrich) stock solution (5 μg/μl) was added to each well and then incubated for 4 h at 37°C. The medium was removed and 150 μl DMSO (Sigma-Aldrich) was added to each well. The absorbance was measured at 490 nm with the microplate reader. Cell viability was expressed as a percentage of the value against the untreated control group. The ratio of growth suppression was calculated by the formula of (OD control − OD experiment )/OD control × 100%, and IC 50 of docetaxel was also calculated while the suppression ratio was 50%.
Colony forming assay
After being transfected with DKK4 siRNA by siRNA Transfection reagent for 48 h, cells were trypsinized, collected and plated into new 35-mm culture dishes at a density of 5 × 10 2 cells/plate. After 7 days, cells were stained with 0.5% crystal violet and counted.
A colony formation could be seen after proliferation for five or more generations of a single cell. The colony formation efficiency was then calculated according to the ratio of the number of colonies to the original number of plated cells.
Invasion ability assay
Invasion activity of the cells was determined by transwell assay as follows. The diluted matrigel was added to the upper chamber insert, and then placed at 37°C for 30 min. A549/DTX cells (5 × 10 4 cells/well)
were seeded in the upper chamber insert with culture medium without FBS but containing 0.5% BSA, while the lower chamber insert contained complete culture medium with 10% FBS to trap invading cells. After 24 h of incubation, cells that penetrated the matrigel-coated membranes and migrated into the lower chamber were stained with 0.5% crystal violet and photographed. The invasion ability was quantified by counting crystal violet-stained cells.
Cell apoptosis assay 
Statistical analysis
Statistical analyses were conducted using the GraphPad Prism 5.0 and SPSS 16.0 software packages. Data were presented as the mean ± SE and were analyzed using the Student's t-test. Significant difference was set at P < 0.05.
Results
Dkk4 expression is significantly increased in A549/DTX cells
The abnormal expression of DKK4 has been previously reported to be closely associated with development of various cancers, such as colorectal, colorectal, liver and pancreatic carcinomas. However, there is still no report about role of DKK4 on lung cancer and its association with the chemoresistance of lung cancer. Our preliminary results based on the limited amount of clinical specimens have proved that DKK4 is overexpressed in lung glandular epithelial tissues of docetaxel-resistant NSCLC patients ( Supplementary Fig. S1 ).
In the study of the chemoresistance mechanisms of lung cancer, we found that DKK4 exhibited abnormal upregulation in A549/DTX cells. As shown in Fig. 1A , DKK4 expression in A549/DTX cells was~5 folds higher than that in parental A549 cells at transcriptional level. In addition, DKK4 expression at translation level was also significantly increased in A549/DTX cells when compared with that in A549 cells (Fig. 1B,C) . As a secreted protein, DKK4 concentration in the supernatant of culture medium in vitro was also detected. The results showed that DKK4 concentration in culture medium was significantly increased in A549/DTX cells compared with that in A549 cells (Fig. 1D) . The above results suggested that DKK4 expression was upregulated in A549/DTX cells compared with that in A549 cells at both mRNA and protein levels.
DKK4 overexpression decreases the sensitivity of A549 cells to docetaxel
To explore whether DKK4 abnormal upregulation is associated with docetaxel resistance, we further analyzed the sensitivity of DKK4-ovexpressed A549 cells to docetaxel in vitro. As shown in Fig. 2A , docetaxel exhibited a less efficient cytotoxic effect on the growth of A549/DTX cells than on the growth of A549 cells.
To figure out whether increased docetaxel resistance of A549/ DTX cells is correlated with DKK4 upregulation, DKK4 overexpression vector was transfected into A549 cells to increase DKK4 expression. DKK4 overexpression was achieved at both mRNA and protein levels, and reached the highest level when A549 cells was transfected with vector at the concentration of 4 μg (Fig. 2B,C) .
The viability of A549 cells with or without DKK4 overexpression was assessed by MTT assay after exposure to docetaxel. Docetaxel exhibited a less efficient cytotoxic effect on the growth of A549 cells after DKK4 transfection at the concentration of 4 μg compared with control (Fig. 2D) . The above results indicated that DKK4 overexpression decreases the sensitivity of A549 cells to docetaxel.
DKK4-knockdown sensitizes A549/DTX cells to cytotoxicity induced by docetaxel
To further explore the role of DKK4 in docetaxel resistance, small interfering RNA (siRNA) technology was used to knockdown DKK4 expression in A549/DTX cells. As shown in Fig. 3A ,B, DKK4 silencing was achieved at both mRNA and protein levels in A549/DTX cells transfected with DKK4 siRNA compared with cells transfected with scrambled siRNA. Then, we chose the optimal concentration of DKK4 siRNA (10 nM) to carry out the subsequent experiments.
Then, the viability of A549/DTX cells with or without DKK4-knockdown was assessed by MTT assay after exposure to docetaxel. As shown in Fig. 3C , docetaxel exhibited a mild cytotoxic effect on the growth of A549/DTX cells by inhibiting the growth of A549/ DTX cells in a dose-dependent manner; and such cytotoxic effect was much more significant in A549/DTX cells with DKK4-knockdown. Similar results were also observed by calculating docetaxel IC 50 of the A549/DTX cells with or without DKK4 (Fig. 3D) . The above results of cell viability assay indicate that DKK4 silencing sensitizes A549/ DTX cells to docetaxel through inducing cell growth inhibition.
DKK4-knockdown decreases A549/DTX cell proliferation and invasion in vitro
To further explore the role of DKK4, we evaluated the effects of DKK4-knockdown on the proliferation and invasion capacity of A549/ DTX cells in vitro. The colony formation assay results showed that number of colonies and colony formation efficiency were clearly decreased after DKK4-knockdown, which further confirmed that DKK4 inhibited the growth of A549/DTX cells (Fig. 4A,B) . In addition, the invasion capacity of A549/DTX cells was evaluated by transwell experiment, and the invaded cells were counted under a light microscope. The number of cells suffered a significant decrease in DKK4-knockdown A549/DTX cells compared with that in control cells (Fig. 4C) . According to the above results, DKK4-knockdown decreases the proliferation and invasion capacity of A549/DTX cells.
DKK4-knockdown sensitizes A549/DTX cells to apoptosis induced by docetaxel
To examine whether the reduction in cell growth in A549/DTX cells by DKK4-knockdown is related to the induction of apoptosis, A549/DTX cells with or without DKK4-knockdown was assessed by dual-staining with Annexin V-FITC/PI after exposure to docetaxel. As shown in Fig. 5A ,B, the percentage of apoptotic cells was obviously decreased in A549/DTX cells when compared with that in A549 cells treated with docetaxel, and the percentage of apoptotic cells was significantly increased in A549/DTX cells with DKK4-knockdown compared with that in control A549/DTX cells. The above results indicate that DKK4-knockdown sensitizes A549/DTX cells to docetaxel through inducing cell apoptosis.
DKK4 silencing sensitizes docetaxel-induced A549/DTX cell apoptosis via activating the JNK pathway
To determine which pathway is involved in the induction of apoptosis by docetaxel, further experiments were conducted. The activation of JNK is associated with apoptosis in response to various cellular stresses. With regard to cancer, several reports on JNKrelated apoptosis in several cancers have been published. Among DKK family members, DKK3 and DKK1 induce apoptosis through the activation of JNK in prostate, testicular, breast cancers, placental choriocarcinoma and mesothelioma. Thus, activation of JNK may also play an important role in apoptosis induced by DKK4-knockdown in A549/DTX cells. Our results showed that JNK was significantly phosphorylated with its expression unchanged in DKK4-knockdown A549/DTX cells after exposure to docetaxel compared with that in control cells (Fig. 6A) . Further results showed that the blockade of JNK activation with SP600125 which is an anthrapyrazole inhibitor of JNK in DKK4-knockdown A549/DTX cells significantly reduced the percentage of apoptotic cells compared with that in control cells (Fig. 6B) . Furthermore, we determined the expression of key cellular proteins involved in apoptosis after JNK activation was blocked by SP600125. The results showed that SP600125 could inhibit caspase 3 activation characterized by the inhibition of cleaved caspase 3, and promote anti-apoptotic BCL-2 expression in DKK4-knockdown A549/DTX cells compared with that in control cells (Fig. 6C-E) . These results indicate that DKK4-knockdown enhances docetaxel-induced A549/DTX cell apoptosis via activating the JNK pathway.
Discussion
Docetaxel is currently the standard second-line chemotherapeutic agent for NSCLC, but drug resistance greatly limits its efficiency in clinical treatment [6, 17] . Therefore, it is necessary to figure out the mechanisms of docetaxel resistance to lung cancer. DKK4 is a member of DKK family which includes four members acting as secreted antagonists of Wnt/β-catenin signaling [18] . Wnt/β-catenin signaling plays an important role in embryogenesis, tissue homeostasis, and tumor development [19] . Since Wnt proteins participate in various types of cancer development and progression, the association of DKKs with cancer are widely concerned. Recent studies have revealed the association of DKK4 with a broad range of solid tumors including colorectal, liver and pancreatic carcinomas. For example, knockdown of DKK4 enhances cell growth and invasiveness of esophageal cancer cells and colorectal-cancer cells [20, 21] . However, the expression pattern of DKK4 and its function are poorly understood in lung cancer so far.
In the present study, we found that the expression of DKK4 was significantly up-regulated in docetaxel-resistant human lung adenocarcinoma A549 cells for the first time, which indicates that DKK4 expression might be correlated with docetaxel resistance. Over the showed that the growth and invasion of A549/DTX cells decreased significantly after DKK4-knockdown, which indicates that knockdown of DKK4 may sensitize A549/DTX cells to cytotoxicity induced by docetaxel. Moreover, the percentage of apoptotic cells induced by docetaxel in A549/DTX cells after DKK4-knockdown was increased significantly, suggesting that DKK4 silencing sensitized A549/DTX cells to docetaxel through inducing cell apoptosis. Our findings demonstrated that DKK4 plays a critical role in mediating chemoresistance to docetaxel, and that DKK4 depletion may contribute to the improvement of lung cancer therapy. To gain insights into the possible molecular mechanism underlying the effect of DKK4 on docetaxel resistance in A549/DTX cells, the involvement of apoptosis-related signaling pathways was investigated, focusing on the intrinsic pathway. The JNKs are master protein kinases that regulate many physiological processes, including inflammatory responses, morphogenesis, cell proliferation, differentiation, survival, apoptosis and death [24] . It is increasingly apparent that activation of JNKs is involved in cancer development and progression, and that depletion of the individual JNKs can suppress tumorigenesis depending on the tissue specificity [25] [26] [27] . However, whether the JNK pathway is involved in DKK4-mediated apoptosis inhibition in A549/DTX cells remains unknown currently. Our results showed that when the expression of DKK4 was down-regulated in A549/DTX cells, phosphorylation of JNK level was significantly increased, which was accompanied by an enhanced sensitivity to docetaxel. Moreover, the blockade of JNK with SP600125 in DKK4-knockdown A549/DTX cells significantly reversed docetaxel-induced apoptosis, suggesting that JNK pathway might be an essential signaling pathway participated in the regulation of DKK4-mediated sensitivity to docetaxel.
In summary, DKK4 upregulation is a critical mediator of docetaxel sensitivity in A549/DTX cells. With DKK4 silencing, the acquired drug resistance to docetaxel is reversed, demonstrating that inhibition of DKK4 is essential for reversing docetaxel resistance. Though JNK activation is involved in DKK4-mediated docetaxel resistance, the underlying mechanisms involved in this process still remain to be explored. Based on our results, we may conclude that appropriate combination of docetaxel application and DKK4 inhibition or depletion might be a promising therapeutic approach in treating NSCLC.
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